yeah i know but only 7 fiddy a share??? seems low to me
Analyst, Boris Peaker, said, "The meeting reaffirmed our confidence in the commercial potential of Erivedge. Consistent with our prior comments, we do not see any near-term competitors to Erivedge. This is important not only from a direct competitive perspective, but also because the royalty agreement between Roche and Curis includes a provision for royalty rate reduction in case of a competitor launch for the same indication. Curis's wholly owned pipeline assets (CUDC-101 and CUDC-907) showed encouraging initial data, but in our view it is too early to model these assets individually.